Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Development of a Vaccine Candidate Based on Surface-Displayed Particles of from the MTB39A Protein.
Int J Mol Sci
January 2025
Key Laboratory of Ministry of Education for Protection and Utilization of Special Biological Resources in Western China, School of Life Sciences, Ningxia University, Yinchuan 750021, China.
Tuberculosis (TB), a human and animal disease caused by (), has the highest global mortality rate after coronavirus disease 2019 (COVID-19) and poses a major public health threat globally. Since 1890, vaccine candidates for various forms of TB have been developed for different age groups, but these vaccine candidates have not provided intended protection in adolescents and adults in clinical trials. To help prevent and control the spread of TB, the development of a safe and effective TB vaccine is imperative.
View Article and Find Full Text PDFManagement of Recurrent Ventriculoperitoneal Shunt Infections in Adult Patients.
Antibiotics (Basel)
January 2025
Department of Medical Biochemistry, Faculty of Medicine, Istanbul Atlas University, 34303 Istanbul, Turkey.
The objective of this study was to evaluate the demographic, clinical, laboratory, and microbiological features of ventriculoperitoneal shunt (VPS) infections through a 13-year retrospective study. VPS bacterial agents and their antibiotic susceptibility were also investigated through the occurrence of single VPS (SVPS) and recurrent VPS (RVPS) infections. This study included 110 patients with SVPS infections and 55 patients with RVPS infections.
View Article and Find Full Text PDFPharmacokinetic Analysis of an Isoniazid Suspension Among Spanish Children Under 6 Years of Age.
Antibiotics (Basel)
January 2025
Malalties Infeccioses i Resposta Inflamatòria Sistèmica en Pediatria, Servei d'Infectologia, Institut de Recerca Pediàtrica Sant Joan de Déu, 08950 Barcelona, Spain.
: Isoniazid (INH) remains a first-line drug for the treatment of tuberculosis (TB) in young children. In 2010, the WHO recommended an increase in the daily dose of INH up to 10 (7-15) mg/kg. Currently, there are no INH suspensions available in Europe.
View Article and Find Full Text PDFA Cross-Sectional, Descriptive Qualitative Study of Information Counselling During Tuberculosis Treatment in South Africa: Awareness of XDR-TB Patients on Ototoxic Effects.
Int J Environ Res Public Health
January 2025
School of Human & Community Development, Faculty of Humanities, University of the Witwatersrand, Johannesburg 2050, South Africa.
Ototoxicity is a significant adverse effect associated with second-line anti-tuberculosis (TB) medications, particularly in treating extensively drug-resistant TB (XDR-TB). This study investigated the awareness of ototoxic effects among adults with XDR-TB undergoing treatment in South Africa, specifically exploring the role of information counselling on ototoxic symptoms, the timing of counselling, the content covered, and the management pathways available. This cross-sectional, descriptive qualitative study was conducted at Brooklyn Chest Hospital in the Western Cape.
View Article and Find Full Text PDFCharacteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis.
Lancet Child Adolesc Health
February 2025
Stellenbosch University, Faculty of Medicine and Health Sciences, Department of Paediatrics and Child Health, Desmond Tutu TB Centre, Tygerberg, South Africa.
Background: There are few data on the treatment of children and adolescents with multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis, especially with more recently available drugs and regimens. We aimed to describe the clinical and treatment characteristics and their associations with treatment outcomes in this susceptible population.
Methods: We conducted a systematic review and individual participant data meta-analysis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!